Increased apoptosis of peripheral blood lymphocytes and its association with interleukin-18 in patients with active untreated adult-onset Still's disease

Arthritis Care and Research

Volumn 57, Issue 8, 2007, Pages 1530-1538

  Chen, Der Yuan ^a,b   Hsieh, Tsu Yi ^a,b   Hsieh, Chia Wei ^a,b   Lin, Fang Ju ^a,b   Lan, Joung Liang ^a,b,c,d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Adult onset Still's disease; Apoptosis; Apoptosis regulating genes; Interleukin 18; Systemic lupus erythematosus

Indexed keywords

CASPASE 3; FAS ANTIGEN; FAS LIGAND; INTERLEUKIN 18; LIPOCORTIN 5; PROPIDIUM IODIDE; PROTEIN BCL 2; PROTEIN P53;

ADULT; APOPTOSIS; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; JUVENILE RHEUMATOID ARTHRITIS; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REMISSION; STAINING; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION;

ADULT; APOPTOSIS; CASE-CONTROL STUDIES; CASPASE 3; DOSE-RESPONSE RELATIONSHIP, DRUG; FAS LIGAND PROTEIN; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; FEMALE; HUMANS; INTERLEUKIN-18; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTES; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; RECOMBINANT PROTEINS; RNA, MESSENGER; STILL'S DISEASE, ADULT-ONSET; TUMOR SUPPRESSOR PROTEIN P53;

EID: 37349015936     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23088     Document Type: Article

References (52)

1. Mountz JD, Zhou T, Su X, Wu J, Cheng J. The role of programmed cell death as an emerging new concept for the pathogenesis of autoimmune disease. Clin Immunol Immunopathol 1996;80(3 Suppl 2):S2-14.
2. Nagata S. Apoptosis by death factor. Cell 1997;88:355-65.
3. Nagata S, Golstein P. The Fas death factor. Science 1995;267:1449-56.
4. Ju ST, Panka DJ, Cui H, Ettinger R, el-Khatib M, Sherr DH, et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995;373:444-8.
5. Ito RM, Terasaki S, Itoh J, Katoh H, Yonehara S, Nose M. Rheumatic diseases in an MRL strain of mice with a deficit in the functional Fas ligand. Arthritis Rheum 1997;40:1054-63.
6. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998;281:1322-6.
7. Sionov RV, Haupt Y. Apoptosis by p53: mechanisms, regulation, and clinical implications. Springer Semin Immunopathol 1998;19:345-62.
8. Bywaters EG. Still's disease in the adult. Ann Rheum Dis 1971;30:121-33.
9. Ohta A, Yamaguchi M, Kaneoka H, Nagayoshi T, Hiida M. Adult Still's disease: review of 228 cases from the literature. J Rheumatol 1987;14:1139-46.
10. Chen DY, Lan JL, Lin FJ, Hsieh TY, Wen MC. A predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still's disease. Ann Rheum Dis 2004;63:1300-6.
11. Zhang X, Brunner T, Carter L, Dutton RW, Rogers P, Bradley L, et al. Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J Exp Med 1997;185:1837-49.
12. Chen DY, Lan JL, Lin FJ, Hsieh TY. Proinflammatory cytokine profiles in the sera and pathological tissues of patients with active untreated adult onset Still's disease. J Rheumatol 2004;31:2189-98.
13. Kawashima M, Yamamura M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, et al. Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum 2001;44:550-60.
14. Dao T, Ohashi K, Kayano T, Kurimoto M, Okamura H. Interferon-gamma- inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. Cell Immunol 1996;173:230-5.
15. Wong CK, Li EK, Ho CY, Lam CW. Elevation of plasma interleukin-18 concentration is correlated with disease activity in systemic lupus erythematosus. Rheumatology (Oxford) 2000;39:1078-81.
16. Lorenz HM, Grunke M, Hieronymus T, Herrmann M, Kuhnel A, Manger B, et al. In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune disease. Arthritis Rheum 1997;40:306-17.
17. Emlen W, Niebur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 1994;152:3685-92.
18. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi S, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992;19:424-30.
19. Pouchot J, Sampalis JS, Beaudet F, Carette S, Decary F, Salusinsky-Sternbach M, et al. Adult Still's disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore) 1991;70:118-36.
20. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
21. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
22. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labeled Annexin V. J Immunol Methods 1995;184:39-51.
23. Chandrasekar B, Vemula K, Surabhi RM, Li-Weber M, Owen-Schaub LB, Jensen LE, et al. Activation of intrinsic and extrinsic proapoptotic signaling pathways in interleukin-18-mediated human cardiac endothelial cell death. J Biol Chem 2004;279:20221-33.
24. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
25. Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res 1996;6:995-1001.
26. Courtney PA, Crockard AD, Williamson K, McConnell J, Kennedy RJ, Bell AL. Lymphocyte apoptosis in systemic lupus erythematosus: relationships with Fas expression, serum soluble Fas and disease activity. Lupus 1999;8:508-13.
27. Nicoletti I, Migliorati G, Pagliacci MC, Riccardi C. A rapid simple method for measuring apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-9.
28. Koopman G, Reutlingsperger CP, Kuitjen GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994;84:1415-20.
29. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates and functions during apoptosis. Annu Rev Biochem 1999;68:383-424.
30. Smolewska E, Brozik H, Smolewski P, Biernacka-Zielinska M, Darzynkiewicz Z, Stanczyk J. Apoptosis of peripheral blood lymphocytes in patients with juvenile idiopathic arthritis [published erratum appears in Ann Rheum Dis 2003;62:1126]. Ann Rheum Dis 2003;62:761-3.
31. Pignatti P, Massa M, Travaglino P, Meazza C, Martini A, De Benedetti F. Activation-induced cell death and Fas-induced apoptosis in patients with systemic or pauciarticular juvenile idiopathic arthritis. Clin Exp Rheumatol 2001;19:339-44.
32. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995;378:88-91.
33. Muhl H, Pfeilschifter J, Anti-inflammatory properties of proinflammatory interferon-gamma. Int Immunopharmacol 2003;3:1247-55.
34. Amerio P, Frezzolini A, Abeni D, Teofoli P, Girardelli CR, De Pita O, et al. Increased IL-18 in patients with systemic lupus erythematosus: relations with Th-1, Th-2, pro-inflammatory cytokines and disease activity. IL-18 is a marker of disease activity but does not correlate with pro-inflammatory cytokines. Clin Exp Rheumatol 2002;20:535-8.
35. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ. Induction of apoptosis in mature T-cell by tumor necrosis factor. Nature 1995;377:348-51.
36. Georgescu L, Vakkalanka RK, Elkon KB, Crow MK. Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand. J Clin Invest 1997;100:2622-33.
37. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995;268:1347-9.
38. Sneller MC, Wang J, Dale JK, Strober W, Middelton LA, Choi Y, et al. Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood 1997;89:1341-8.
39. Chen Y, Inobe JI, Marks R, Gonnella P, Kuchroo VK, Weiner HL. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 1995;376:177-80.
40. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature 1997;390:350-1.
41. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. Macrophages that have ingested apoptotic cells in vitro inhibit pro-inflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998;101:890-8.
42. Ohtsuki T, Micallef MJ, Kohno K, Tanimoto T, Ikeda M, Kurimoto M. Interleukin 18 enhances Fas ligand expression and induces apoptosis in Fas-expressing human myelomonocytic KG-1 cells. Anticancer Res 1997;17:3253-8.
43. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992;148:2207-16.
44. Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998;41:1241-50.
45. Tas SW, Quartier P, Botto M, Fossati-Jimack L. Macrophages from patients with SLE and rheumatoid arthritis have defective adhesion in vitro, while only SLE macrophages have impaired uptake of apoptotic cells. Ann Rheum Dis 2006;65:216-21.
46. Vermes I, Haanen C, Richel DJ, Schaafsma MR, Kalsbeek-Batenburg E, Reutelingsperger CP. Apoptosis and secondary necrosis of lymphocytes in culture. Acta Haematol 1997;98:8-13.
47. Baumann I, Kolowos W, Voll RE, Manger B, Gaipl U, Neuhuber WL, et al. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum 2002;46:191-201.
48. Trebeden-Negre H, Weill B, Foumier C, Batteux F. B cell apoptosis accelerates the onset of murine lupus. Eur J Immunol 2003;33:1603-12.
49. Gershov D, Kim S, Brot N, Elkon KB. C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 2000;192:1353-64.
50. Schwarz-Eywill M, Heilig B, Bauer H, Breitbart A, Pezzutto A. Evaluation of serum ferritin as a marker for adult Still's disease activity. Ann Rheum Dis 1992;51:683-5.
51. Lambotte O, Cacoub P, Costedoat N, Le Moel G, Amoura Z, Piette JC. High ferritin and low glycosylated ferritin may also be a marker of excessive macrophage activation. J Rheumatol 2003;30:1027-8.
52. Cush JJ, Medsger TA Jr, Christy WC, Herbert DC, Cooperstein LA. Adult-onset Still's disease: clinical course and outcome. Arthritis Rheum 1987;30:186-94.